{
    "ticker": "AVDX",
    "name": "Avidity Biosciences, Inc.",
    "description": "Avidity Biosciences, Inc. is a biotechnology company focused on advancing the next generation of targeted therapies for serious diseases. Founded in 2012, Avidity\u2019s innovative approach centers around its proprietary AOC (Antibody Oligonucleotide Conjugate) platform, which combines the specificity of antibodies with the power of RNA therapies. This unique technology aims to deliver therapeutic oligonucleotides directly to specific cells, improving efficacy and reducing potential off-target effects. Avidity is dedicated to developing treatments for various diseases, with a particular focus on muscle disorders, including Duchenne muscular dystrophy (DMD). The company is committed to transforming patient outcomes through the development of precision medicines that harness the body\u2019s natural mechanisms of action. Avidity is also exploring applications of its platform in other therapeutic areas, including oncology and rare diseases, positioning itself at the forefront of the rapidly evolving field of gene therapy. The company\u2019s mission is to unlock the potential of RNA-based therapies through innovative science and technology, striving to bring new hope to patients with unmet medical needs.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2012",
    "website": "https://www.aviditybiosciences.com",
    "ceo": "Sarah Boyce",
    "social_media": {
        "twitter": "https://twitter.com/AvidityBio",
        "linkedin": "https://www.linkedin.com/company/avidity-biosciences/"
    },
    "investor_relations": "https://investors.aviditybiosciences.com",
    "key_executives": [
        {
            "name": "Sarah Boyce",
            "position": "CEO"
        },
        {
            "name": "Jeffrey H. Bock",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "AOC 1001"
            ]
        }
    ],
    "seo": {
        "meta_title": "Avidity Biosciences, Inc. | Targeted RNA Therapeutics",
        "meta_description": "Explore Avidity Biosciences, a biotech company dedicated to developing targeted therapies using its innovative AOC platform. Discover our mission and pipeline.",
        "keywords": [
            "Avidity Biosciences",
            "Biotechnology",
            "RNA Therapeutics",
            "Duchenne Muscular Dystrophy",
            "AOC Platform"
        ]
    },
    "faq": [
        {
            "question": "What does Avidity Biosciences do?",
            "answer": "Avidity Biosciences develops targeted therapies using its proprietary AOC platform to deliver oligonucleotides directly to specific cells."
        },
        {
            "question": "Who is the CEO of Avidity Biosciences?",
            "answer": "The CEO of Avidity Biosciences is Sarah Boyce."
        },
        {
            "question": "Where is Avidity Biosciences located?",
            "answer": "Avidity Biosciences is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are Avidity's main products?",
            "answer": "Avidity's main product is AOC 1001, targeting Duchenne muscular dystrophy."
        },
        {
            "question": "When was Avidity Biosciences founded?",
            "answer": "Avidity Biosciences was founded in 2012."
        }
    ],
    "competitors": [
        "SRPT",
        "BMRN",
        "CRSP",
        "EDIT"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "VRTX"
    ]
}